ClinicalTrials.Veeva

Menu
Wright State Physicians | Pharmacology Translational Unit logo

Wright State Physicians | Pharmacology Translational Unit

Research site

Site insights

Top conditions

Top treatments

Apremilast
Imipramine
Baricitinib
CC-10004
Ixekizumab
ASN002
Risankizumab
Lebrikizumab
Dupilumab
LY3009104

Data sourced from clinicaltrials.gov

Contact this site

Elizabeth Cates

Verified by this site

Active trials

12 of 44 total trials

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue...

Active, not recruiting
Psoriasis
Drug: Apremilast
Locations recently updated

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-...

Enrolling
Moderate to Severe Atopic Dermatitis
Drug: Rezpegaldesleukin
Drug: Placebo

The purpose of this study is to evaluate the safety of efgartigimod PH20 SC over a longer period of time in adult participants with moderate-to-sever...

Invitation-only
Bullous Pemphigoid
Drug: Prednisone
Biological: efgartigimod PH20 SC

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Enrolling
Plaque Psoriasis
Drug: Placebo
Drug: TAK-279

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...

Enrolling
Atopic Dermatitis
Eczema
Drug: Placebo
Drug: Lebrikizumab

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with mode...

Enrolling
Atopic Dermatitis
Eczema
Drug: Lebrikizumab
Drug: Placebo

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Enrolling
Prurigo Nodularis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

The study is a multicenter clinical trial and is designed as a proof-of-concept study to evaluate the efficacy, safety, tolerability, PK, immunogenic...

Enrolling
Atopic Dermatitis
Drug: BSI-045B
Drug: Dupilumab

A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with m...

Enrolling
Discoid Lupus Erythematosus
Drug: Daxdilimab
Drug: Placebo/Daxdilimab
Locations recently updated

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will asse...

Enrolling
Scalp Psoriasis
Genital Psoriasis
Drug: Risankizumab
Drug: Placebo for Risankizumab

Trial sponsors

W
Lilly logo
Amgen logo
AbbVie logo
A
A
A
B
Bristol-Myers Squibb (BMS) logo
Incyte logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems